Merck, Keytruda and Halozyme

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ
A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based pharma giant’s cancer blockbuster,
New version of Merck's Keytruda faces possible patent battle, WSJ reports
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.
Merck injected version of Keytruda faces possible patent challenge: Report
Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent dispute, according to a report by The Wall Street Journal
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a new version of
New version of Merck's cancer drug faces possible patent battle, WSJ reports
Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
New version of Merck's cancer drug faces possible patent battle: reports
Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.
Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says
Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in
Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)
Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics’ (HALO) Buy Rating Reiterated at Benchmark
Benchmark reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a ...
Forbes6d
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...